An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis

Inclusion Criteria:

- Have completed the final active treatment in study JADV (NCT01710358), JADZ
(NCT01711359), JADX (NCT01721057), JADW (NCT01721044), JADA (NCT01185353) or JAGS
(planned start date in August 2014)

Exclusion Criteria:

- Have significant uncontrolled cerebro-cardiovascular (eg, myocardial infarction [MI],
unstable angina, unstable arterial hypertension, severe heart failure, or
cerebrovascular accident), respiratory, hepatic, renal, gastrointestinal, endocrine,
hematologic, neuropsychiatric disorders, or abnormal laboratory values that developed
during a previous baricitinib study that, in the opinion of the investigator, pose an
unacceptable risk to the participant if investigational product continues to be
administered

- Have a known hypersensitivity to baricitinib or any component of this investigational
product

- Had investigational product permanently discontinued at any time during a previous
baricitinib study

- Had temporary investigational product interruption at the final study visit of a
previous baricitinib study and, in the opinion of the investigator, this poses an
unacceptable risk for participation in the study

- Have any other condition that, in the opinion of the investigator, renders the
participant unable to understand the nature, scope, and possible consequences of the
study or precludes the participant from following and completing the protocol